ACC: American College of Cardiology; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADA: American Diabetes Association; Apo: apolipoprotein; ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm; ASPEN: Atorvastatin
Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus; BP: blood pressure; CARDS: Collaborative Atorvastatin
Diabetes Study; CETP: cholesterol ester transfer protein; CHD: coronary heart disease; CVD: cardiovascular disease; EUROASPIRE: EUROpean Action on Secondary Prevention through Intervention to Reduce Events; FIELD: Fenofibrate
Intervention and Event Lowering in Diabetes; FXR: farnesoid X receptor; GLOWS: Glucose-Lowering effect of Welchol
Study; GLP-1: glucagon-like peptide-1; HDL-C: high-density lipoprotein cholesterol; HPS: Heart Protection Study; IDL: intermediate-density lipoprotein; LDL-C: low-density lipoprotein cholesterol; NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III; NEFA: nonesterified (free) fatty acid; NHANES: United States National Health and Nutritional Examination Survey; NMR: nuclear magnetic resonance; Non-HDL-C: non-high-density lipoprotein cholesterol; RAAS: renin-angiotensin-aldosterone system; SHIELD: Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes; TC: total cholesterol; TG: triglyceride; TNT: Treating to New Targets; UKPDS: United Kingdom Prospective Diabetes Study; VLDL: very-low-density lipoprotein cholesterol.